Targeted radiation therapy for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new radioactive drug, Lutetium-177 FAP-75, for people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target and deliver radiation directly to cancer cells, potentially slowing tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced solid tumor (cancer that has spread or cannot be removed) that has stopped responding to standard treatments.
- You are between 18 and 80 years old.
- You are able to care for yourself (ECOG score 0-1) and expected to live at least 4 months.
- Your cancer shows up on a special PET/CT scan that looks for a protein called FAP.
- Your blood counts, liver, and kidney function are within acceptable levels (your doctor will check this).
- You have not had radiation therapy or certain other cancer treatments within the past 4-6 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new radioactive drug (Lutetium-177 BL-ARC001) for people with advanced solid tumors, including stomach, bowel, and other cancers. It aims to see if the treatment is safe and how well it works.
This trial tests a new radioactive drug (177Lu-BL-ARC001) for people with advanced lung, breast, head and neck, or other solid tumors that have not responded to standard treatments. It aims to see if the drug can target and shrink tumors while limiting side effects.
This trial tests a new drug, NRT6020, that targets a protein called FAP found on many solid tumors. It aims to see if the drug is safe and how it works in people with advanced solid tumors that have not responded to other treatments.
This trial tests a radioactive drug called 177Lu-CTR-FAPI for people with advanced solid tumors that have not responded to standard treatments. It targets tumors that show a specific protein (FAP) on PET scans. The study focuses on certain cancers like pancreatic, breast, and soft tissue sarcoma.
This trial tests a radioactive drug called Lutetium-177 Oxodotreotide (a type of PRRT) for people with advanced neuroendocrine tumors that have already been treated with other therapies and are still growing. The drug targets somatostatin receptors on tumor cells to deliver radiation directly to the cancer.
This trial tests how safe and effective a targeted radiation medicine (177Lu-FAP-2286) is for people with advanced solid cancers that have limited treatment options. It may help by delivering radiation directly to cancer-related targets and shrinking tumors.
Hear when a new Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.